Safety and immunogenicity of a combined pentavalent diphtheria, tetanus, acellular pertussis, inactivated poliovirus and Haemophilus influenzae type b-tetanus conjugate vaccine in the infants, compared with a whole cell pertusis pentavalent vaccine

Pediatric Infectious Disease Journal

Volumn 16, Issue 12, 1997, Pages 1113-1112

  Dagan, Ron ^a   Igbaria, Karim ^a   Piglansky, Lolita ^a   Melamed, Rimma ^a   Willems, Paul ^b   Grossi, Annalisa ^b   Kaufhold, Achim ^b  

^a BEN GURION UNIVERSITY OF THE NEGEV   (Israel)

^b GLAXOSMITHKLINE BIOLOGICALS   (Belgium)

Author keywords

Acellular pertussis; Combined vaccines; Diphtheria; Haemophilus influenzae b; Immunization; Poliovirus; Tetanus

Indexed keywords

BACTERIAL POLYSACCHARIDE; DIPHTHERIA PERTUSSIS TETANUS HAEMOPHILUS INFLUENZAE TYPE B VACCINE; HEMAGGLUTININ; PARACETAMOL; PENTACOQ; PERTUSSIS TOXIN; PERTUSSIS VACCINE; POLIOMYELITIS VACCINE; RIBITOL; TETANUS TOXOID; UNCLASSIFIED DRUG;

ARTICLE; CLINICAL PROTOCOL; CLINICAL TRIAL; CONTROLLED STUDY; CONVULSION; DRUG MIXTURE; DRUG SAFETY; FEMALE; FEVER; HUMAN; HUMAN EXPERIMENT; IMMUNE RESPONSE; IMMUNIZATION; IMMUNOGENICITY; INFANT; INJECTION PAIN; MALE; NORMAL HUMAN; PRACTICE GUIDELINE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RASH; VACCINATION;

ANTIBODIES, BACTERIAL; ANTIBODIES, VIRAL; DIPHTHERIA-TETANUS-PERTUSSIS VACCINE; FEMALE; HAEMOPHILUS VACCINES; HUMANS; INFANT; MALE; POLIOVIRUS VACCINE, INACTIVATED; TETANUS TOXOID;

EID: 0031441454     PISSN: 08913668     EISSN: None     Source Type: Journal    
DOI: 10.1097/00006454-199712000-00004     Document Type: Article

References (41)

1. Watemberg N, Dagan R, Arbelli Y, et al. Safety and immunogenicity of Haemophilus type b-tetanus protein conjugate vaccine, mixed in the same syringe with diphtheria-tetanus-petussis vaccine in young infants. Pediatr Infect Dis J 1991; 10:758-61.
2. Clemens JD, Ferreccio C, Levine MM, et al. Impact of Haemophilus influenzae type b polysaccharide-tetanus protein conjugate vaccine on responses to concurrently administered diphtheria-tetanus-pertussis vaccine. JAMA 1992;267: 673-8.
3. Ferreccio C, Clemens J, Avendano A, et al. The clinical and immunologic response of Chilean infants to Haemophilus influenzae type b polysaccharide-tetanus protein conjugate vaccine co-administered in the same syringe with diphtheria-tetanus toxoids-pertussis vaccine at 2, 4 and 6 months of age. Pediatr Infect Dis J 1991;10:764-71.
4. Mulholland EK, Ahonkhai VI, Greenwood AM, et al. Safety and immunogenicity of Haemophilus influenzae type b-Neisseria meningitidis group B outer membrane protein complex conjugate vaccine mixed in the syringe with diphtheria-tetanus-pertussis vaccine in young Gambian infants. Pediatr Infect Dis J 1993;12:632-7.
5. Scheifele D, Barreto L, Meekison W, et al. Can Haemophilus influenzae type b-tetanus toxoid conjugate vaccine be combined with diphtheria toxoid-pertussis vaccine-tetanus toxoid? Can Med Assoc J 1993;149:1105-12.
6. Avendano A, Ferreccio C, Lagos R, et al. Haemophilus influenzae type b polysaccharide-tetanus protein conjugate vaccine does not depress serologic responses to diphtheria, tetanus or pertussis antigens when coadministered in the same syringe with diphtheria-tetanus-pertussis vaccine at two, four and six months of age. Pediatr Infect Dis J 1993;12:638-43.
7. Paradiso PR, Hogerman DA, Madore DV, et al. Safety and immunogenicity of a combined diphtheria, tetanus, pertussis and Haemophilus influenzae type b vaccine in young infants. Pediatrics 1993;92:827-32.
8. Kaplan SL, Lauer BA, Ward MA, et al. Immunogenicity and safety of Haemophilus influenzae type b-tetanus protein conjugate alone or mixed with diphtheria-tetanus-pertussis vaccine in infants. J Pediatr 1994;124:323-7.
9. Dagan R, Botujansky C, Watemberg N, et al. Safety and immunogenicity in young infants of Haemophilus b-tetanus protein conjugate vaccine, mixed in the same syringe with diphtheria-tetanus-pertussis-enhanced inactivated poliovirus vaccine. Pediatr Infect Dis J 1994;13:356-61.
10. Gold R, Scheifele D, Barreto L, et al. Safety and immunogenicity of Haemophilus influenzae vaccine (tetanus toxoid conjugate) administered concurrently or combined with diphtheria and tetanus toxoids, pertussis vaccine and inactivated poliomyelitis vaccine to healthy infants at two, four and six months of age. Pediatr Infect Dis J 1994;13:348-55.
11. Miller MA, Meschievitz CK, Ballanco GA, Daum RS. Safety and immunogenicity of PRPT combined with DTP: excretion of capsular polysaccharide and antibody response in the immediate post-vaccination period. Pediatrics 1995;95: 522-7.
12. Eskola J. Analysis of Haemophilus influenzae type b conjugate and diphtheria-tetanus-pertussis combination vaccines. J Infect Dis 1996;174:S302-5.
13. Mulholland EK, Hoestermann A, Ward JI, Maine N, Ethevenaux C, Greenwood BM. The use of Haemophilus influenzae type b-tetanus toxoid conjugate vaccine mixed with diphtheria-tetanus-pertussis vaccine in Gambian infants. Vaccine 1996;14:905-9.
14. Edwards KM, Meade B, Decker MD, et al. Comparison of 13 acellular pertussis vaccines: overview and serologic response. Pediatrics 1995;96:548-57.
15. Bogaerts H, Capiau C, Hauser P, Mareschal JC, Mélot V, Simons D. Overview of the clinical development of a diphtheria-tetanus-acellular pertussis vaccine. J Infect Dis 1996;174: S276-80.
16. Trollfors B, Taranger J, Lagergard T, et al. A placebo-controlled trial of a pertussis-toxoid vaccine. N Engl J Med 1995;333:1045-50.
17. Schmitt HJ, Wirsing von König CH, Neiss A, et al. Efficacy of acellular pertussis vaccine in early childhood after household exposure. JAMA 1996;275:37-41.
18. Gustafsson L, Hallander HO, Olin P, Reizenstein E, Storsäter J. A controlled trial of a two-component acellular, a five-component acellular, and a whole cell pertussis vaccine. N Engl J Med 1996;334:349-55.
19. Greco D, Salmaso S, Mastrantonio P, et al. A controlled trial of two acellular vaccines and one whole-cell vaccine against pertussis. N Engl J Med 1996;334:341-8.
20. Advisory Committee on Immunization Practices (ACIP). Poliomyelitis prevention in the United States: introduction of a sequential vaccination schedule of inactivated poliovirus vaccine followed by oral poliovirus vaccine. MMWR Morbid Mortal Wkly Rep 1997;46(RR-3).
21. Eskola J, Ölander RM, Hovi T, Litmanen L, Peltola S, Käyhty H. Randomised trial of the effect of co-administration with acellular pertussis DTP vaccine on immunogenicity of Haemophilus influenzae type b conjugate vaccine. Lancet 1996; 348:1688-92.
22. Schmitt HJ. Immunogenicity and reactogenicity of 2 Hib tetanus conjugate vaccines administered by reconstituting with DTPa or given as separate injections [Abstract G63]. Presented at the 35th Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco, September 17 to 20, 1995.
23. Shinefield H, Black S, Ray P, et al. Safety of combined acellular pertussis DtaP-HbOC vaccine (Lederle-Praxis) in infants [Abstract G72]. Presented at the 35th Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco, September 17 to 20, 1995.
24. Greenberg DP, Wong VK, Partridge S, Howe BJ, Jing J, Ward JI. Evaluation of a new combination vaccine that incorporates diphtheria-tetanus-acellular pertussis (DtaP), hepatitis B (HB) and Haemophilus influenzae type b (Hib) conjugate (PRPT) vaccines [Abstract G70]. Presented at the 35th Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco September 17 to 20, 1995.
25. Zepp F, Schmitt HJ, Kaufhold A, et al. Evidence for induction of polysaccharide specific B-cell-memory in the 1st year of life: plain Haemophilus influenzae type b-PRP (Hib) boosters children primed with a tetanus-conjugate Hib-DTPa-HBV combined vaccine. Eur J Pediatr 1997;156:18-24.
26. Camargo ME, Silveira L, Furura JA, Oliveira EP, Germek OA. Immunoenzymatic assay of anti-diphtheric toxin antibodies in human serum. J Clin Microbiol 1984;20:772-4.
27. Melville-Smith ME, Seagroatt VA, Watkins JT. A comparison of enzyme-linked immunosorbent assay (ELISA) with the toxin neutralization test in mice as a method for the estimation of tetanus antitoxin in human sera. J Biol Stand 1983; 11:137-44.
28. Granström M, Thoren M, Blennow M, Tiru M, Sato Y. Acellular pertussis vaccine in adults: adverse reactions and immune response. Eur J Clin Microbiol 1987;6:18-21.
29. Karpinsky KF, Hayward S, Tryphonas H. Statistical considerations in the quantitation of serum immunoglobulin levels using the enzyme-linked immunosorbent assay (ELISA). J Immunol Methods 1987;103:189-94.
30. Sato Y, Sato H, Izimiya, et al. Role of antibody to filamentous hemagglutinin and to leukocytosis promoting factor-hemagglutinin in immunity to pertussis. In: Robbins JB, Hill JC, Sardoff JC ed. Seminars in infectious disease: bacterial vaccines. New York: Thieme-Stratton, Inc., 1982:380-5.
31. Standard procedure for determining immunity to poliovirus using the microneutralisation test (WHO/EPI/GEN 93.9).
32. Radioimmunoassay for serum Haemophilus influenzae type b capsular polysaccharide antibodies (WHO document BS/ 90.1634).
33. Englund JA, Decker MD, Edwards KM, Pichichero ME, Steinhoff MC, Anderson EL. Acellular and whole cell pertussis vaccines as booster doses: a multicenter study. Pediatrics 1994;93:37-43.
34. Decker MD, Edwards KM, Steinhoff MC, et al. Comparison of 13 acellular pertussis vaccines: adverse reactions. Pediatrics 1995;96:557-66.
35. Halperin SA, Eastwood BJ, Barreto L, et al. Adverse reactions and antibody response to four doses of acellular or whole cell pertussis vaccine combined with diphtheria and tetanus toxoids in the first 19 months of life. Vaccine 1996; 14:767-72.
36. Blumberg DA, Mink CA, Cherry JD, et al. Comparison of acellular and whole-cell pertussis component diphtheria-tetanus-pertussis vaccines in infants. J Pediatr 1991;119: 194-204.
37. Pichichero ME, Green JL, Francis AB, Marsocci SM, Lynd Murphy AM, Buscarino C. Antibody response and reactions to completion of a four-dose series with a two-or three-component acellular pertussis vaccine compared to a whole cell pertussis vaccine. Scand J Infect Dis 1996;28:159-63.
38. Pichichero M, Latiolais T, Bernstein D, et al. Immunogenicity and safety of a combination DTaP/PRPT vaccine in 2, 4 and 6 month-old infants [Abstract G097]. Presented at the 36th Interscience Conference on Antimicrobial Agents and Chemotherapy, New Orleans, September 15 to 18, 1996.
39. Liese JG, Harzer E, Hosbach P, Froeschle J, Meschievitz CK, Belohradsky. Hib antibody response of a combined DTaP-PRPT conjugate vaccine compared to separate injections in infants [Abstract G105]. Presented at the 36th Interscience Conference on Antimicrobial Agents and Chemotherapy, New Orleans, September 15 to 18, 1996.
40. Stanley F, Condon R. Comparison of two Hib tetanus conjugate vaccines. Presented at the Seventh International Congress for Infectious Disease, Hong Kong, June, 1996.
41. Schmitt HJ. Immunogenicity and reactogenicity of 2 Hib tetanus conjugate vaccines administered by reconstituting with DTPa or given as separate injections [Abstract G63]. Presented at the 35th Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco, September 17 to 20, 1995.